ABCG2 and cancer: Similarly, expression of the other ABC-transporters did not change after BGJ 398 treatment (Supplementary Table S2), thereby suggesting about BGJ 398′s ability to sensitize MDR-overexpressing cancer cells to chemotherapeutic agents due to its interaction with this ABC transporter.